Roche, a global pharma major has launched monoclonal antibody atezolizumab under the brand name Tecentriq in India. The drug will be useful for the treatment of patients suffering from lung and bladder cancer.
In a statement, the Roche said Tecentriq has shown to extend survival and improve the quality of life in the approved indications.
The product has been approved in India “for two types of cancers: non-small cell lung cancer (NSCLC) and Urothelial Carcinoma, a type of bladder and urinary tract cancer”, statement further added.
The pharma major has announced that the drug will now be available to patients in India on the prescription of oncologists.
Responding to the development, Lara Bezerra, Managing Director, Roche Products India Pvt Ltd said, “Bringing Tecentriq to India reflects Roche’s commitment to bring global innovations to the country.”
“Roche has helped transform the treatment of cancer globally, and will continue to set newer standards of care for cancer patients in India,” Bezerra further stated.
Tecentriq is a monoclonal antibody used for treatment of metastatic non-small cell lung cancer and metastatic urothelial carcinoma. It is a cancer immunotherapy drug that is designed to work with body’s natural defense system.